Suppr超能文献

[炎症性消化系统疾病患者和回肠造口术患者粪便α-1-抗胰蛋白酶的定性研究]

[Qualitative study of fecal alpha-1-antitrypsin in patients with inflammatory digestive disease and patients with ileostomy].

作者信息

Colombel J F, Mizon C, Chekkouri N, Balduyck M, Chaussade S, Becuwe C, Degand P, Mizon J, Cortot A

机构信息

Clinique des Maladies de l'Appareil Digestif et de la Nutrition, Hôpital C.-Huriez, CHU, Lille.

出版信息

Gastroenterol Clin Biol. 1991;15(4):301-5.

PMID:2060740
Abstract

Alpha-1-antitrypsin is a glycoprotein which is excreted in feces under three different forms of molecular weight 38, 45 and 51 kDa. The 45 and 38 kDa forms are the result of a partial or total removal of the carbohydrate moiety, respectively. We determined the molecular forms of fecal alpha-1-antitrypsin in 10 controls, 13 patients with protein-losing enteropathy other than inflammatory bowel disease, 70 patients with active (n = 55) (CDAI greater than 150) and inactive (n = 15) (CDAI less than 150) Crohn's disease, 14 patients with active (n = 12) and inactive (n = 2) ulcerative colitis, and 17 patients with ileostomy. Fecal 38 kDa alpha-1-antitrypsin was found in all controls, all patients with protein-losing enteropathy, in 82 percent of patients with inactive inflammatory bowel disease, and in 20 percent of patients with active inflammatory bowel disease. In contrast, the 51 kDa and 45 kDa forms were present in feces of 80 percent of patients with active inflammatory bowel disease, and in only 17 percent of patients with inactive inflammatory bowel disease. Patients with Crohn's disease and the 51 kDa form (n = 39) had significantly higher values of activity index (CDAI) and orosomucoid than patients with Crohn's disease and the 38 kDa form (n = 26) (P less than 0.01). Deglycosylated 38 kDa alpha-1-antitrypsin was never recovered in ileostomy samples. This suggests that deglycosylation of alpha-1-antitrypsin occurred in the colon and is impaired in patients with active inflammatory bowel disease.

摘要

α-1-抗胰蛋白酶是一种糖蛋白,它以分子量分别为38 kDa、45 kDa和51 kDa的三种不同形式排泄于粪便中。45 kDa和38 kDa的形式分别是碳水化合物部分被部分或全部去除的结果。我们测定了10名对照者、13名非炎性肠病的蛋白丢失性肠病患者、70名活动期(n = 55)(CDAI大于150)和非活动期(n = 15)(CDAI小于150)的克罗恩病患者、14名活动期(n = 12)和非活动期(n = 2)的溃疡性结肠炎患者以及17名回肠造口术患者粪便中α-1-抗胰蛋白酶的分子形式。在所有对照者、所有蛋白丢失性肠病患者、82%的非活动期炎性肠病患者以及20%的活动期炎性肠病患者的粪便中发现了38 kDa的α-1-抗胰蛋白酶。相比之下,51 kDa和45 kDa的形式存在于80%的活动期炎性肠病患者的粪便中,而仅存在于17%的非活动期炎性肠病患者的粪便中。患有克罗恩病且为51 kDa形式(n = 39)的患者的活动指数(CDAI)和类粘蛋白值显著高于患有克罗恩病且为38 kDa形式(n = 26)的患者(P小于0.01)。在回肠造口术样本中从未检测到去糖基化的38 kDaα-1-抗胰蛋白酶。这表明α-1-抗胰蛋白酶的去糖基化发生在结肠,且在活动期炎性肠病患者中受损。

相似文献

引用本文的文献

1
Molecular form of faecal alpha 1 antitrypsin in patients with Crohn's disease.
Gut. 1992 Apr;33(4):572. doi: 10.1136/gut.33.4.572-a.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验